Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination.

[Guest guest]

Vaccine. 2011 Aug 1. [Epub ahead of print]

Presence of immune memory and immunity to hepatitis B virus in adults after

neonatal hepatitis B vaccination.

Zhu CL, Liu P, Chen T, Ni Z, Lu LL, Huang F, Lu J, Sun Z, Qu C.

Source

State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese

Academy of Medical Sciences & Peking Union Medical College, 17 Panjiayuan Nanli,

Beijing 100021, China.

Abstract

Neonatal vaccination against hepatitis B virus (HBV) infection was launched in

the 1980s in Qidong, China, where HBV and hepatocellular carcinoma were highly

prevalent. Presence of immune memory and immunity against HBV in adults needs to

be clarified. From a cohort of 806 who received plasma-derived Hep-B-Vax as

neonates and were consecutively followed at ages 5, 10, and 20years, 402

twenty-four-year-old adults were recruited for booster test. Among them 4 (1%)

were found to be HBsAg(+), 27 (6.7%) were HBsAg(-)/anti-HBc(+), 121 (30.2%) were

HBsAg(-)anti-HBc(-)anti-HBs(+), and 252 (62.4%) were

HBsAg(-)anti-HBc(-)anti-HBs(-). Of them, 141 subjects with HBsAg(-)anti-HBc(-)

were boosted with 10-μg recombinant HBV vaccine on day-0 and 1-month. The

conversion rates of anti-HBs ≥10mIU/ml on D10-12 and 1-month post-booster were

71.4% and 87.3% respectively in the vaccinees who were anti-HBs(+) at age 5,

higher than in those who were anti-HBs(-) at age 5, 57.5% and 80.0%

respectively, but no statistically significant. After the second dose of

booster, all subjects with anti-HBs(+) at age 5 had anti-HBs >500mIU/ml.

However, 6/40 subjects, with anti-HBs(-) at age 5, had anti-HBs <10mIU/ml,

geometric mean concentration was 3.6 (95% CI 2.0-7.7). Of the subjects received

booster, 44 subjects were determined the presence of T cell immunity on D10-12,

41 had HBsAg-specific T cells detectable, including 7/10 subjects whose anti-HBs

were <10mIU/ml 10-12days post-booster. Among 27 HBsAg(-)anti-HBc(+) subjects, 19

had detectable serum HBV-DNA, and an " a " epitope mutation was found in 1/5 HBV

isolates. One subject who was anti-HBc(+) at age 20 converted into HBsAg(+)

4years later. The adults received neonatal HBV vaccination had immune memory and

immunity against HBV infection. However, 31.9% of neonatal HBV vaccinees who

responded weakly at an early age might be susceptible to HBV infection after

childhood.

Copyright © 2011. Published by Elsevier Ltd.

PMID: 21816197 [PubMed - as supplied by publisher]

[Guest guest]

Vaccine. 2011 Aug 1. [Epub ahead of print]

Presence of immune memory and immunity to hepatitis B virus in adults after

neonatal hepatitis B vaccination.

Zhu CL, Liu P, Chen T, Ni Z, Lu LL, Huang F, Lu J, Sun Z, Qu C.

Source

State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese

Academy of Medical Sciences & Peking Union Medical College, 17 Panjiayuan Nanli,

Beijing 100021, China.

Abstract

Neonatal vaccination against hepatitis B virus (HBV) infection was launched in

the 1980s in Qidong, China, where HBV and hepatocellular carcinoma were highly

prevalent. Presence of immune memory and immunity against HBV in adults needs to

be clarified. From a cohort of 806 who received plasma-derived Hep-B-Vax as

neonates and were consecutively followed at ages 5, 10, and 20years, 402

twenty-four-year-old adults were recruited for booster test. Among them 4 (1%)

were found to be HBsAg(+), 27 (6.7%) were HBsAg(-)/anti-HBc(+), 121 (30.2%) were

HBsAg(-)anti-HBc(-)anti-HBs(+), and 252 (62.4%) were

HBsAg(-)anti-HBc(-)anti-HBs(-). Of them, 141 subjects with HBsAg(-)anti-HBc(-)

were boosted with 10-μg recombinant HBV vaccine on day-0 and 1-month. The

conversion rates of anti-HBs ≥10mIU/ml on D10-12 and 1-month post-booster were

71.4% and 87.3% respectively in the vaccinees who were anti-HBs(+) at age 5,

higher than in those who were anti-HBs(-) at age 5, 57.5% and 80.0%

respectively, but no statistically significant. After the second dose of

booster, all subjects with anti-HBs(+) at age 5 had anti-HBs >500mIU/ml.

However, 6/40 subjects, with anti-HBs(-) at age 5, had anti-HBs <10mIU/ml,

geometric mean concentration was 3.6 (95% CI 2.0-7.7). Of the subjects received

booster, 44 subjects were determined the presence of T cell immunity on D10-12,

41 had HBsAg-specific T cells detectable, including 7/10 subjects whose anti-HBs

were <10mIU/ml 10-12days post-booster. Among 27 HBsAg(-)anti-HBc(+) subjects, 19

had detectable serum HBV-DNA, and an " a " epitope mutation was found in 1/5 HBV

isolates. One subject who was anti-HBc(+) at age 20 converted into HBsAg(+)

4years later. The adults received neonatal HBV vaccination had immune memory and

immunity against HBV infection. However, 31.9% of neonatal HBV vaccinees who

responded weakly at an early age might be susceptible to HBV infection after

childhood.

Copyright © 2011. Published by Elsevier Ltd.

PMID: 21816197 [PubMed - as supplied by publisher]